Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

抗体偶联药物 (antibody-drug conjugates，ADCs)正在引领肿瘤治疗的新革命，通过结合抗体的高特异性和化疗药物的强大杀伤力，为肿瘤治疗提供了一种更加精准且有效的手段。本文综述了ADCs的研发历程、国内外上市情况、临床试验情况以及监管法规，并重点探讨了ADCs在新药临床研究申请 (investi gational new ...

根据协议，乐普生物授予ArriVent在大中华区以外地区开发、制造和商业化MRG007的全球独家许可。乐普生物将获得总计4700万美元的一次性首付款和近期里程碑付款，和最高达11.6亿美元的开发、注册和销售等里程碑付款。

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing deals. | A year after going public, ArriVent BioPharma is continuing to ...

AntibodyChina 2025第八届抗体药物及ADC深度聚焦峰会将于2025年2月27-28日在南京盛大举行。本次峰会专注于探讨 抗体药物及ADC研发中的核心策略，从双抗与ADC的最新科研成果，到大规模生产中的技术瓶颈与应对策略，再到合作创新模式的探索与实践， 全方位、多角度地呈现 抗体药物领域的最新动态与未来趋势。

1月15日，Axcynsis Therapeutics Pte ...

Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...

Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

In this video, Xiuning Le, MD, PhD, discusses the state of the pipeline for developing EGFR-mutated lung cancer treatments.